Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Diabetes / Metabolic Rheumatology Gastroenterology Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT07598617

The Co-Production and Evaluation of the Computerised Cognitive Assessment for Preclinical Alzheimer’s Disease (CoCoA-PAD)

The Co-Production and Evaluation of the Computerised Cognitive Assessment for Preclinical Alzheimer’s Disease (CoCoA-PAD) — Recruiting • Neurology • NCT07598617.

📅 20 May 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07598617
Sponsor
University of Plymouth
Start
2026-05-05
ClinicaliQ Trial Snapshot
  • The Co-Production and Evaluation of the Computerised Cognitive Assessment for Preclinical Alzheimer’s Disease (CoCoA-PAD) — Recruiting • Neurology • NCT07598617.
  • Sponsor: University of Plymouth.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Background. Healthcare professionals can now diagnose the earliest stages of Alzheimer's disease (early-AD) and new drugs are effective at slowing the disease. The National Health Service (NHS) in the United Kingdom has started to develop plans for how to implement these key achievements into clinical practice, so that patients can receive timely diagnosis and treatment. Cognitive assessments measure someone's memory and thinking skills and are required for an early-AD diagnosis. There are concerns that the NHS does not have the workforce to deliver cognitive assessments, and that this will delay…

Eligibility Snapshot
  • Recruitment Criteria for Subjective Cognitive Decline and Mild Cognitive Impairment Subjective Cognitive Decline Inclusion Criteria * >3.38 on IQCODE Self-Report items 1-7 (PROTECT) OR * ≥4 on SCD-Q9 (non-Protect) AND * Age ≥65 years * Onset of SCD within the last 5 years * English as a first language * Normal demographically adjusted performance on standardised cognitive tests * Specific Race and Education (using stratified sampling approach)

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Dementia: Assessment, Management and Support (NICE NG97)
Neurology · 25 Mar 2026
Use cognitive testing (MMSE or MoCA) combined with appropriate imaging to confirm dementia diagnosis • Prescribe acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine)…
View guideline →
Clinical Brief
Anaemia and the new dementia link
Neurology · BBC Health · 07 May 2026
Key Takeaways for Clinical Practice Anaemia has been identified as a newly recognised risk factor for dementia, suggesting haemoglobin levels should be…
View brief →
Guideline
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
Neurology · 07 May 2026
Oxybutynin is effective for neurogenic detrusor overactivity in patients aged 6+ years with spinal cord injury or spina bifida—consider as first-line antimuscarinic…
View guideline →
Guideline
Motor Neurone Disease: Assessment and Management (NICE NG42)
Neurology · 27 Mar 2026
Refer suspected MND urgently to a specialist neurology centre for diagnosis confirmation by an MND-experienced neurologist using clinical examination, EMG/NCS, imaging, and…
View guideline →
Clinical Brief
Breakthrough £90,000 Alzheimer’s drugs unlikely to benefit patients, report suggests
Neurology · BBC Health · 16 Apr 2026
New anti-amyloid monoclonal antibodies for Alzheimer's disease show clinically minimal benefits despite high cost (£90,000), with disease progression slowing by only 25-35%…
View brief →
Clinical Brief
My daughter has childhood dementia and may not live past 16
Neurology · BBC Health · 01 Apr 2026
Key Clinical Takeaways Childhood dementia represents a group of rare progressive neurodegenerative disorders with devastating outcomes—Sophia's case illustrates the severe functional decline…
View brief →